These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16471038)

  • 1. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients.
    Garg MB; Sakoff JA; Ackland SP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2201-5. PubMed ID: 21719363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.
    Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography.
    Andersen A; Kasperlik-Zaluska AA; Warren DJ
    Ther Drug Monit; 1999 Jun; 21(3):355-9. PubMed ID: 10365653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells.
    Hermansson V; Asp V; Bergman A; Bergström U; Brandt I
    Arch Toxicol; 2007 Nov; 81(11):793-801. PubMed ID: 17487473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer.
    Schteingart DE; Sinsheimer JE; Benitez RS; Homan DF; Johnson TD; Counsell RE
    Anticancer Res; 2012 Jul; 32(7):2711-20. PubMed ID: 22753730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
    Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A
    J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
    Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
    Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of GC/MS/SIM for rapid determination of plasma levels of o,p'-DDD, o,p'-DDE and o,p'-DDA.
    Inouye M; Mio T; Sumino K
    Clin Chim Acta; 1987 Dec; 170(2-3):305-14. PubMed ID: 3436064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.
    van Aalderen W; van Seters AP; Backer ET; Chang PC; van Krieken JH; Moolenaar AJ
    Neth J Med; 1992 Oct; 41(3-4):161-70. PubMed ID: 1470288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
    Lindhe O; Skogseid B
    Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of single and repeated in vitro exposure of ovarian follicles to o,p'-DDT and p,p'-DDT and their metabolites.
    Wójtowicz AK; Gregoraszczuk EL; Ptak A; Falandysz J
    Pol J Pharmacol; 2004; 56(4):465-72. PubMed ID: 15520502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of o,p'-DDE, heptachlor, and 17beta-estradiol on vitellogenin gene expression and the growth hormone/insulin-like growth factor-I axis in the tilapia, Oreochromis mossambicus.
    Davis LK; Visitacion N; Riley LG; Hiramatsu N; Sullivan CV; Hirano T; Grau EG
    Comp Biochem Physiol C Toxicol Pharmacol; 2009 May; 149(4):507-14. PubMed ID: 19101654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) in rats.
    Reif VD; Sinsheimer JE
    Drug Metab Dispos; 1975; 3(1):15-25. PubMed ID: 234830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.